Lantern Pharma Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 5.44 million compared to USD 3.87 million a year ago. Basic loss per share from continuing operations was USD 0.51 compared to USD 0.36 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.37 USD | -1.29% | -3.76% | +25.47% |
Jun. 12 | Lantern Pharma Secures Composition of Matter Patent for LP-284 in Japan | MT |
May. 29 | Transcript : Lantern Pharma Inc. - Special Call |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.47% | 57.77M | |
+40.80% | 53.67B | |
+36.75% | 38.86B | |
-8.05% | 38.76B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |
- Stock Market
- Equities
- LTRN Stock
- News Lantern Pharma Inc.
- Lantern Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024